School of Medicine Homepage
Emory University Shield
  • About
    • Our Vision
    • Academic Departments
    • Our Leadership
    • Health Care Partnerships
    • Diversity, Equity, & Inclusion
    • Location
    • Supporting Our People
    • Our Faculty
    • History
    • News
    • Events
    • Contact Us
  • Education
    • Degree and Certificate Programs
    • Academic Departments
    • Residents & Fellows
    • Postdoctoral Training
    • Continuing Medical Education
    • Admissions
    • Cost and Financial Aid
    • Student Resources
  • Research
    • Research Innovation
    • Conducting Research
    • Core Facilities
    • Research Centers
    • Research Training
    • Academic Departments
    • Find a Researcher
    • Research News
  • Clinical Experience
    • Where We Work
    • Caring for a Diverse Population
    • Faculty Clinical Experience
    • Advanced Patient Care
    • Academic Departments
    • Community Learning
  • Giving
  • Directory

Directory section navigation

  • Faculty Profiles

Emory University School of Medicine

  • About
    • Sub link
      Our Vision
    • Sub link
      Academic Departments
    • Sub link
      Our Leadership
    • Sub link
      Health Care Partnerships
    • Sub link
      Diversity, Equity, & Inclusion
    • Sub link
      Location
    • Sub link
      Supporting Our People
    • Sub link
      Our Faculty
    • Sub link
      History
    • Sub link
      News
    • Sub link
      Events
    • Sub link
      Contact Us
  • Education
    • Sub link
      Degree and Certificate Programs
    • Sub link
      Academic Departments
    • Sub link
      Residents & Fellows
    • Sub link
      Postdoctoral Training
    • Sub link
      Continuing Medical Education
    • Sub link
      Admissions
    • Sub link
      Cost and Financial Aid
    • Sub link
      Student Resources
  • Research
    • Sub link
      Research Innovation
    • Sub link
      Conducting Research
    • Sub link
      Core Facilities
    • Sub link
      Research Centers
    • Sub link
      Research Training
    • Sub link
      Academic Departments
    • Sub link
      Find a Researcher
    • Sub link
      Research News
  • Clinical Experience
    • Sub link
      Where We Work
    • Sub link
      Caring for a Diverse Population
    • Sub link
      Faculty Clinical Experience
    • Sub link
      Advanced Patient Care
    • Sub link
      Academic Departments
    • Sub link
      Community Learning
  • Giving
  • Directory
  • Home School of Medicine Home
  • Directory

Profile

Srilatha Edupuganti MD

  • Department of Medicine
    Professor
  • (404) 712-1434
  • sedupug@emory.edu
Head shot of Srilatha Edupuganti

Overview

Dr. Edupuganti received her MD degree from Louisiana State University School of Medicine in New Orleans. She completed her residency in Internal Medicine at Parkland Memorial Hospital University of Texas Southwestern Medical Center, and her Infectious Diseases Fellowship at Emory University and the University of North Carolina, Chapel Hill School of Medicine. She also received a MPH in Epidemiology form the University of North Carolina School of Public Health. In September 2006, she joined the faculty of the Division of Infectious Diseases as a member of the Hope Clinic where vaccine clinical trials are conducted.

Dr. Edupugantis research interests are translational research in vaccines and vaccine development. She is based at the Hope Clinic of Emory Vaccine Center and serves as the Medical Director. She has been focused on HIV vaccine development for the past 10 years. She is the Hope Clinic CRS leader for the DAIDS funded Emory-CDC Clinical Trials Unit. She is a site investigator/co-investigator for the HIV Vaccine Trials Network (HVTN) studies that are being conducted at the Hope clinic. She serves as the Clinical Core leader for translational immunology projects funded by CCHI of NIAID.

She is an attending physician at Emory Healthcare.

She is involved in the teaching, administrative activities and conferences of the Division of Infectious Diseases including lectures, interviews, journal club, case of the week and research seminars. At the Hope Clinic, she participates in the training of junior, international, and minority investigators in vaccine clinical trials, methodologies, provides education, prevention, and community outreach services, which includes speaking to community and other groups regarding vaccine development.

Academic Appointment

  • Professor of Medicine, Emory Univesity School of Medicine

Education

Degrees

  • MPH from UNC-School of Public Health
  • MD from Louisiana State University School of Medicine
  • BS from Loyola University

Research

Focus

  • My primary research interest is in translational studies of vaccines and vaccine clinical trials. I have been involved either as a site principal investigator or co-investigator and conducted clinical trials of HIV vaccines, influenza vaccines including H1N1 and avian influenza vaccines, yellow fever vaccine, smallpox vaccine and others. I served as the site principal investigator for several Merck phase I HIV vaccine clinical trials that included DNA vaccines with or without adjuvants, adenovirus vaccines, and canarypox vector based vaccines.

Publications

  • Fixed dosing versus weight-based dosing of HIV-1 prophylactic monoclonal antibodies in adults: a post-hoc, cross-protocol pharmacokinetics modelling study.
    EBioMedicine Volume: 117 Page(s): 105804
    07/01/2025 Authors: Huang Y; Zhang L; Gelderblom H; Seaton KE; Yates NL; Paez CA; Karuna ST; Andrew P; Gamble T; Robinson ST
  • Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans.
    Science Page(s): eadr8382
    05/15/2025 Authors: Willis JR; Prabhakaran M; Muthui M; Naidoo A; Sincomb T; Wu W; Cottrell CA; Landais E; deCamp AC; Keshavarzi NR
  • Mucosal and Systemic Antibody Responses After Boosting With a Bivalent Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
    J Infect Dis
    04/29/2025 Authors: Atmar RL; Lyke KE; Posavad CM; Deming ME; Brady RC; Dobrzynski D; Edupuganti S; Mulligan MJ; Rupp RE; Rostad CA
  • Brief Report: Associations Between Gender and Solicited Adverse Events After Passive Infusion of VRC01 or Placebo in HVTN 704/HPTN 085.
    J Acquir Immune Defic Syndr Volume: 98 Page(s): 340 - 345
    04/01/2025 Authors: Theodore DA; Neradilek M; Gillespie K; Edupuganti S; Hinojosa JC; Lama JR; De La Grecca R; Wu YH; Davis A; Mangini D
  • Pharmacokinetic interaction assessment of an HIV broadly neutralizing monoclonal antibody VRC07-523LS: a cross-protocol analysis of three phase 1 trials in people without HIV.
    BMC Immunol Volume: 26 Page(s): 8
    02/19/2025 Authors: Chawana TD; Walsh SR; Stranix-Chibanda L; Chirenje ZM; Yu C; Zhang L; Seaton KE; Heptinstall J; Zhang L; Paez CA
  • Rare twin cysteine residues in the HIV-1 envelope variable region 1 link to neutralization escape and breadth development.
    Cell Host Microbe Volume: 33 Page(s): 279 - 293.e6
    02/12/2025 Authors: Hesselman MC; Zeeb M; Rusert P; Pasin C; Mamrosh J; Kariuki S; Pichler I; Sickmann M; Kaufmann MM; Schmidt D
  • Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial.
    Clin Infect Dis Volume: 80 Page(s): 223 - 227
    02/05/2025 Authors: Fong Y; Dang L; Zhang B; Fintzi J; Chen S; Wang J; Rouphael NG; Branche AR; Diemert DJ; Falsey AR
  • Retrospective analysis of sex-disaggregated immune responses to ALVAC-HIV and bivalent subtype C gp120/MF59 HIV vaccines.
    Front Immunol Volume: 16 Page(s): 1557009
    01/01/2025 Authors: Ackerley CG; Edupuganti S; Yu C; Roxby AC; Seaton KE; Bekker L-G; Allen M; DeRosa SC; Yates NL; Heptinstall J
  • Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial.
    Lancet HIV Volume: 12 Page(s): e13 - e25
    01/01/2025 Authors: Edupuganti S; Hurt CB; Stephenson KE; Huang Y; Paez CA; Yu C; Yen C; Hanscom B; He Z; Miner MD
  • Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies.
    J Exp Med Volume: 221
    10/07/2024 Authors: Hahn WO; Parks KR; Shen M; Ozorowski G; Janes H; Ballweber-Fleming L; Woodward Davis AS; Duplessis C; Tomai M; Dey AK
  • Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
    J Infect Dis Volume: 230 Page(s): e405 - e415
    08/16/2024 Authors: Chirenje ZM; Laher F; Dintwe O; Muyoyeta M; deCamp AC; He Z; Grunenberg N; Laher Omar F; Seaton KE; Polakowski L
  • Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials.
    Open Forum Infect Dis Volume: 11 Page(s): ofae387
    07/01/2024 Authors: Cantos VD; Neradilek M; Huang Y; Roxby AC; Gillespie K; deCamp AC; Karuna ST; Edupuganti S; Gallardo-Cartagena J; Sanchez J
  • Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Gurin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.
    J Infect Dis Volume: 229 Page(s): 1498 - 1508
    05/15/2024 Authors: Blazevic A; Edwards RL; Xia M; Eickhoff CS; Hamzabegovic F; Meza KA; Ning H; Tennant J; Mosby KJ; Ritchie JC
  • HIV BG505 SOSIP.664 trimer with 3M-052-AF/alum induces human autologous tier-2 neutralizing antibodies.
    medRxiv
    05/09/2024 Authors: Hahn WO; Parks KR; Shen M; Ozorowski G; Janes H; Ballweber-Fleming L; Woodward Davis AS; Duplessis C; Tomai M; Dey AK
  • Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.
    Lancet HIV Volume: 11 Page(s): e285 - e299
    05/01/2024 Authors: Frank I; Li SS; Grunenberg N; Overton ET; Robinson ST; Zheng H; Seaton KE; Heptinstall JR; Allen MA; Mayer KH
  • Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.
    Pharmaceutics Volume: 16
    04/27/2024 Authors: Mayer BT; Zhang L; deCamp AC; Yu C; Sato A; Angier H; Seaton KE; Yates N; Ledgerwood JE; Mayer K
  • Heterologous cAd3-Ebola and MVA-EbolaZ vaccines are safe and immunogenic in US and Uganda phase 1/1b trials.
    NPJ Vaccines Volume: 9 Page(s): 67
    03/29/2024 Authors: Happe M; Hofstetter AR; Wang J; Yamshchikov GV; Holman LA; Novik L; Strom L; Kiweewa F; Wakabi S; Millard M
  • Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
    Nat Commun Volume: 15 Page(s): 2575
    03/22/2024 Authors: Reeves DB; Mayer BT; deCamp AC; Huang Y; Zhang B; Carpp LN; Magaret CA; Juraska M; Gilbert PB; Montefiori DC
  • XBB.1.5 monovalent booster improves antibody binding and neutralization against emerging SARS-CoV-2 Omicron variants.
    bioRxiv
    02/05/2024 Authors: Jain S; Kumar S; Lai L; Linderman S; Malik AA; Ellis ML; Godbole S; Solis D; Sahoo MK; Bechnak K
  • Longitudinal fecal shedding of SARS-CoV-2, pepper mild mottle virus, and human mitochondrial DNA in COVID-19 patients.
    Front Med (Lausanne) Volume: 11 Page(s): 1417967
    01/01/2024 Authors: Liu P; Sablon O; Wang Y; Hilton SP; Khalil L; Ingersoll JM; Truell J; Edupuganti S; Alaaeddine G; Naji A
  • High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
    Nat Commun Volume: 14 Page(s): 8299
    12/14/2023 Authors: Reeves DB; Mayer BT; deCamp AC; Huang Y; Zhang B; Carpp LN; Magaret CA; Juraska M; Gilbert PB; Montefiori DC
  • Natural infection by Zika virus but not DNA vaccination consistently elicits antibodies that compete with two potently neutralising monoclonal antibodies targeting distinct epitopes.
    EBioMedicine Volume: 98 Page(s): 104875
    12/01/2023 Authors: Smith TC; Espinoza DO; Zhu Y; Cardona-Ospina JA; Bowman NM; Becker-Dreps S; Rouphael N; Rodriguez-Morales AJ; Bucardo F; Edupuganti S
  • Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
    Nat Commun Volume: 14 Page(s): 7813
    11/28/2023 Authors: Huang Y; Zhang L; Karuna S; Andrew P; Juraska M; Weiner JA; Angier H; Morgan E; Azzam Y; Swann E
  • Risk of COVID-19 after natural infection or vaccination.
    EBioMedicine Volume: 96 Page(s): 104799
    10/01/2023 Authors: Rick A-M; Laurens MB; Huang Y; Yu C; Martin TCS; Rodriguez CA; Rostad CA; Maboa RM; Baden LR; El Sahly HM
  • Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants.
    NPJ Vaccines Volume: 8 Page(s): 98
    07/11/2023 Authors: Lyke KE; Atmar RL; Dominguez Islas C; Posavad CM; Deming ME; Branche AR; Johnston C; El Sahly HM; Edupuganti S; Mulligan MJ
  • Pharmacokinetic serum concentrations of VRC01 correlate with prevention of HIV-1 acquisition.
    EBioMedicine Volume: 93 Page(s): 104590
    07/01/2023 Authors: Seaton KE; Huang Y; Karuna S; Heptinstall JR; Brackett C; Chiong K; Zhang L; Yates NL; Sampson M; Rudnicki E
  • Counterfactual estimation of efficacy against placebo for novel PrEP agents using external trial data: example of injectable cabotegravir and oral PrEP in women.
    J Int AIDS Soc Volume: 26 Page(s): e26118
    06/01/2023 Authors: Donnell D; Gao F; Hughes JP; Hanscom B; Corey L; Cohen MS; Edupuganti S; Mgodi N; Rees H; Baeten JM
  • Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trials.
    PLoS Pathog Volume: 19 Page(s): e1011469
    06/01/2023 Authors: Mkhize NN; Yssel AEJ; Kaldine H; van Dorsten RT; Woodward Davis AS; Beaume N; Matten D; Lambson B; Modise T; Kgagudi P
  • Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study.
    J Infect Dis Volume: 227 Page(s): 939 - 950
    04/18/2023 Authors: Stieh DJ; Barouch DH; Comeaux C; Sarnecki M; Stephenson KE; Walsh SR; Sawant S; Heptinstall J; Tomaras GD; Kublin JG
  • Trivalent mosaic or consensus HIV immunogens prime humoral and broader cellular immune responses in adults.
    J Clin Invest Volume: 133
    02/15/2023 Authors: Cohen KW; Fiore-Gartland A; Walsh SR; Yusim K; Frahm N; Elizaga ML; Maenza J; Scott H; Mayer KH; Goepfert PA
  • Safety and Immunogenicity of Influenza A/H5N8 Virus Vaccine in Healthy Adults: Durability and Cross-reactivity of Antibody Responses.
    Clin Infect Dis
    01/05/2023 Authors: Neuzil KM; Anderson EJ; Frenck RW; Frey SE; Walter EB; Rupp R; Rotrosen ET; Rouphael NG; Brady RC; Graham I
  • Prediction of serum HIV-1 neutralization titers of VRC01 in HIV-uninfected Antibody Mediated Prevention (AMP) trial participants.
    Hum Vaccin Immunother Volume: 18 Page(s): 1908030
    12/31/2022 Authors: Huang Y; Zhang L; Eaton A; Mkhize NN; Carpp LN; Rudnicki E; DeCamp A; Juraska M; Randhawa A; McDermott A
  • Neutralizing antibody responses in patients hospitalized with SARS-CoV-2 Delta or Omicron infection.
    J Clin Invest Volume: 132
    12/01/2022 Authors: Linderman SL; Lai L; Bocangel Gamarra EL; Lau MS; Edupuganti S; Surie D; Tenforde MW; Chappell JD; Mohr NM; Gibbs KW
  • Antibody Response to COVID-19 mRNA Vaccine in Patients With Lung Cancer After Primary Immunization and Booster: Reactivity to the SARS-CoV-2 WT Virus and Omicron Variant.
    J Clin Oncol Volume: 40 Page(s): 3808 - 3816
    11/20/2022 Authors: Valanparambil RM; Carlisle J; Linderman SL; Akthar A; Millett RL; Lai L; Chang A; McCook-Veal AA; Switchenko J; Nasti TH
  • Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A 6-month prospective analysis of the COVID-19 Prevention in Emory Healthcare Personnel (COPE) Study.
    Infect Control Hosp Epidemiol Volume: 43 Page(s): 1664 - 1671
    11/01/2022 Authors: Howard-Anderson JR; Adams C; Dube WC; Smith TC; Sherman AC; Edupuganti N; Mendez M; Chea N; Magill SS; Espinoza DO
  • Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens.
    EBioMedicine Volume: 84 Page(s): 104271
    10/01/2022 Authors: Huang Y; Zhang Y; Seaton KE; De Rosa S; Heptinstall J; Carpp LN; Randhawa AK; McKinnon LR; McLaren P; Viegas E
  • First-in-human evaluation of safety and pharmacokinetics of intravenous or subcutaneous infusions of PGT121.141.LS, an anti-V3 HIV-1 broadly neutralizing antibody in healthy volunteers without HIV
    Volume: 25 Page(s): 229 - 229
    08/01/2022 Authors: Edupuganti S; Hurt C; Stephenson K; Huang Y; Paez C; Gamble T; Yu C; Yen C; Regenold S; Chege W
  • Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
    Lancet Infect Dis Volume: 22 Page(s): 1210 - 1220
    08/01/2022 Authors: Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S
  • Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant.
    Cell Rep Med Volume: 3 Page(s): 100679
    07/19/2022 Authors: Lyke KE; Atmar RL; Islas CD; Posavad CM; Szydlo D; Paul Chourdhury R; Deming ME; Eaton A; Jackson LA; Branche AR
  • Infusion Reactions After Receiving the Broadly Neutralizing Antibody VRC01 or Placebo to Reduce HIV-1 Acquisition: Results From the Phase 2b Antibody-Mediated Prevention Randomized Trials.
    J Acquir Immune Defic Syndr Volume: 89 Page(s): 405 - 413
    04/01/2022 Authors: Takuva S; Karuna ST; Juraska M; Rudnicki E; Edupuganti S; Anderson M; De La Grecca R; Gaudinski MR; Sehurutshi A; Orrell C
  • Homologous and Heterologous Covid-19 Booster Vaccinations.
    N Engl J Med Volume: 386 Page(s): 1046 - 1057
    03/17/2022 Authors: Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE
  • EVITA Dengue: a cluster-randomized controlled trial to EValuate the efficacy of Wolbachia-InfecTed Aedes aegypti mosquitoes in reducing the incidence of Arboviral infection in Brazil.
    Trials Volume: 23 Page(s): 185
    03/02/2022 Authors: Collins MH; Potter GE; Hitchings MDT; Butler E; Wiles M; Kennedy JK; Pinto SB; Teixeira ABM; Casanovas-Massana A; Rouphael NG
  • Occupational risk factors for severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection among healthcare personnel: A cross-sectional analysis of subjects enrolled in the COVID-19 Prevention in Emory Healthcare Personnel (COPE) study.
    Infect Control Hosp Epidemiol Volume: 43 Page(s): 381 - 386
    03/01/2022 Authors: Howard-Anderson JR; Adams C; Sherman AC; Dube WC; Smith TC; Edupuganti N; Chea N; Magill SS; Espinoza DO; Zhu Y
  • Antibody response to SARS-CoV-2 mRNA vaccine in lung cancer patients: Reactivity to vaccine antigen and variants of concern.
    medRxiv
    01/23/2022 Authors: Valanparambil R; Carlisle J; Linderman S; Akthar A; Millett RL; Lai L; Chang A; McCook A; Switchenko J; Nasti T
  • EVALUATION AND APPLICATION OF NOVEL SEROLOGIC TOOLS FOR ASSESSING ZIKA VIRUS SPECIFIC IMMUNITY FOR SURVEILLANCE AND TRANSLATIONAL RESEARCH
    Volume: 105 Page(s): 190 - 190
    11/01/2021 Authors: Smith TC; Espinoza DO; Zhu Y; Becker-Dreps S; Bowman NM; Edupuganti S; Rodriguez-Morales AJ; Cardona-Ospina JA; Bucardo F; de Silva AM
  • Evaluation of a SARS-CoV-2 Capture IgM Antibody Assay in Convalescent Sera.
    Microbiol Spectr Volume: 9 Page(s): e0045821
    10/31/2021 Authors: Ha B; Jadhao S; Hussaini L; Gibson T; Stephens K; Salazar L; Ciric C; Taylor M; Rouphael N; Edupuganti S
  • Human Antibody Responses Following Vaccinia Immunization Using Protein Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular Cytotoxicity Responses.
    J Infect Dis Volume: 224 Page(s): 1372 - 1382
    10/28/2021 Authors: Frey SE; Stapleton JT; Ballas ZK; Rasmussen WL; Kaufman TM; Blevins TP; Jensen TL; Davies DH; Tary-Lehmann M; Chaplin P
  • Heterologous SARS-CoV-2 Booster Vaccinations - Preliminary Report.
    medRxiv
    10/15/2021 Authors: Atmar RL; Lyke KE; Deming ME; Jackson LA; Branche AR; El Sahly HM; Rostad CA; Martin JM; Johnston C; Rupp RE
  • Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.
    Science Volume: 373 Page(s): 1372 - 1377
    09/17/2021 Authors: Pegu A; O'Connell SE; Schmidt SD; O'Dell S; Talana CA; Lai L; Albert J; Anderson E; Bennett H; Corbett KS
  • Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and Tcells.
    Cell Rep Med Volume: 2 Page(s): 100354
    07/20/2021 Authors: Cohen KW; Linderman SL; Moodie Z; Czartoski J; Lai L; Mantus G; Norwood C; Nyhoff LE; Edara VV; Floyd K
  • Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities A Randomized Clinical Trial
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Volume: 326 Page(s): 46 - 55
    07/06/2021 Authors: Cohen MS; Nirula A; Mulligan MJ; Novak RM; Marovich M; Yen C; Stemer A; Mayer SM; Wohl D; Brengle B
  • Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019.
    Open Forum Infect Dis Volume: 8 Page(s): ofab315
    07/01/2021 Authors: Anderson B; Smith Z; Edupuganti S; Yan X; Masi CM; Wu HM
  • Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells.
    medRxiv
    06/18/2021 Authors: Cohen KW; Linderman SL; Moodie Z; Czartoski J; Lai L; Mantus G; Norwood C; Nyhoff LE; Edara VV; Floyd K
  • Evaluation of Cellular and Serological Responses to Acute SARS-CoV-2 Infection Demonstrates the Functional Importance of the Receptor-Binding Domain.
    J Immunol Volume: 206 Page(s): 2605 - 2613
    06/01/2021 Authors: Mantus G; Nyhoff LE; Kauffman RC; Edara VV; Lai L; Floyd K; Shi P-Y; Menachery VD; Edupuganti S; Scherer EM
  • A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline Findings.
    J Acquir Immune Defic Syndr Volume: 87 Page(s): 680 - 687
    05/01/2021 Authors: Mgodi NM; Takuva S; Edupuganti S; Karuna S; Andrew P; Lazarus E; Garnett P; Shava E; Mukwekwerere PG; Kochar N
  • Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
    J Acquir Immune Defic Syndr Volume: 87 Page(s): 671 - 679
    05/01/2021 Authors: Edupuganti S; Mgodi N; Karuna ST; Andrew P; Rudnicki E; Kochar N; deCamp A; De La Grecca R; Anderson M; Karg C
  • Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant.
    Cell Host Microbe Volume: 29 Page(s): 516 - 521.e3
    04/14/2021 Authors: Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R
  • Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition.
    N Engl J Med Volume: 384 Page(s): 1003 - 1014
    03/18/2021 Authors: Corey L; Gilbert PB; Juraska M; Montefiori DC; Morris L; Karuna ST; Edupuganti S; Mgodi NM; deCamp AC; Rudnicki E
  • Reduced binding and neutralization of infection- and vaccine-induced antibodies to the B.1.351 (South African) SARS-CoV-2 variant.
    bioRxiv
    02/22/2021 Authors: Edara VV; Norwood C; Floyd K; Lai L; Davis-Gardner ME; Hudson WH; Mantus G; Nyhoff LE; Adelman MW; Fineman R
  • VRC01 antibody prevention of HIV
    Volume: 24
    02/01/2021 Authors: Corey L; Gilbert PB; Mgodi NM; Edupuganti S; Cohen MS
  • Neutralization profiles of HIV-1 subtype C breakthrough viruses from the Southern African VRC01 AMP trial (HVTN 703/HPTN 081)
    Volume: 24
    02/01/2021 Authors: Mkhize NN; Mapengo RE; Bekker V; Modise T; Kgagudi P; Lambson BE; Kaldine H; van Dorsten RT; Mgodi N; Karuna S
  • Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trials.
    EBioMedicine Volume: 64 Page(s): 103203
    02/01/2021 Authors: Huang Y; Naidoo L; Zhang L; Carpp LN; Rudnicki E; Randhawa A; Gonzales P; McDermott A; Ledgerwood J; Lorenzo MMG
  • A flexible, pan-species, multi-antigen platform for the detection and monitoring of SARS-CoV-2-specific antibody responses.
    medRxiv
    01/27/2021 Authors: Shen H; Forgacs D; Chapla D; Moremen KW; Wells L; Hamer SA; Tompkins SM; Ross TM; Rouphael N; Edupuganti S
  • Application of SARS-CoV-2 Serology to Address Public Health Priorities.
    Front Public Health Volume: 9 Page(s): 744535
    01/01/2021 Authors: Sherman AC; Smith T; Zhu Y; Taibl K; Howard-Anderson J; Landay T; Pisanic N; Kleinhenz J; Simon TW; Espinoza D
  • COVID-19 Serology at Population Scale: SARS-CoV-2-Specific Antibody Responses in Saliva.
    J Clin Microbiol Volume: 59
    12/17/2020 Authors: Pisanic N; Randad PR; Kruczynski K; Manabe YC; Thomas DL; Pekosz A; Klein SL; Betenbaugh MJ; Clarke WA; Laeyendecker O
  • Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults.
    Vaccines (Basel) Volume: 8
    12/07/2020 Authors: Edupuganti S; C De Rosa S; Elizaga M; Lu Y; Han X; Huang Y; Swann E; Polakowski L; A Kalams S; Keefer M
  • Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies.
    Curr Protoc Immunol Volume: 131 Page(s): e116
    12/01/2020 Authors: Vanderheiden A; Edara VV; Floyd K; Kauffman RC; Mantus G; Anderson E; Rouphael N; Edupuganti S; Shi P-Y; Menachery VD
  • Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
    Pediatrics Volume: 146
    12/01/2020 Authors: Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM
  • Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study.
    Lancet HIV Volume: 7 Page(s): e688 - e698
    10/01/2020 Authors: Baden LR; Stieh DJ; Sarnecki M; Walsh SR; Tomaras GD; Kublin JG; McElrath MJ; Alter G; Ferrari G; Montefiori D
  • Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans.
    Science Volume: 369 Page(s): 1210 - 1220
    09/04/2020 Authors: Arunachalam PS; Wimmers F; Mok CKP; Perera RAPM; Scott M; Hagan T; Sigal N; Feng Y; Bristow L; Tak-Yin Tsang O
  • Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
    JCI Insight Volume: 5
    07/09/2020 Authors: De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J
  • Duration of Cellular and Humoral Responses after Quadrivalent Human Papillomavirus Vaccination in Healthy Female Adults with or without Prior Type 16 and/or 18 Exposure.
    Vaccines (Basel) Volume: 8
    06/30/2020 Authors: Lai L; Ault K; Rouphael N; Beck A; Domjahn B; Xu Y; Anderson EJ; Cheng A; Nakamura A; Hoagland RJ
  • Rapid Generation of Neutralizing Antibody Responses in COVID-19 Patients.
    Cell Rep Med Volume: 1 Page(s): 100040
    06/23/2020 Authors: Suthar MS; Zimmerman MG; Kauffman RC; Mantus G; Linderman SL; Hudson WH; Vanderheiden A; Nyhoff L; Davis CW; Adekunle O
  • The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
    Sci Immunol Volume: 5
    06/11/2020 Authors: Premkumar L; Segovia-Chumbez B; Jadi R; Martinez DR; Raut R; Markmann A; Cornaby C; Bartelt L; Weiss S; Park Y
  • COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva.
    medRxiv
    05/26/2020 Authors: Randad PR; Pisanic N; Kruczynski K; Manabe YC; Thomas D; Pekosz A; Klein SL; Betenbaugh MJ; Clarke WA; Laeyendecker O
  • The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.
    medRxiv
    05/10/2020 Authors: Premkumar L; Segovia-Chumbez B; Jadi R; Martinez DR; Raut R; Markmann A; Cornaby C; Bartelt L; Weiss S; Park Y
  • Rapid generation of neutralizing antibody responses in COVID-19 patients.
    medRxiv
    05/08/2020 Authors: Suthar MS; Zimmerman M; Kauffman R; Mantus G; Linderman S; Vanderheiden A; Nyhoff L; Davis C; Adekunle S; Affer M
  • Baseline Levels of Influenza-Specific B Cells and T Cell Responses Modulate Human Immune Responses to Swine Variant Influenza A/H3N2 Vaccine.
    Vaccines (Basel) Volume: 8
    03/13/2020 Authors: Lai L; Rouphael N; Xu Y; Sherman AC; Edupuganti S; Anderson EJ; Lankford-Turner P; Wang D; Keitel W; McNeal MM
  • Decreased humoral immunity to mumps in young adults immunized with MMR vaccine in childhood.
    Proc Natl Acad Sci U S A Volume: 116 Page(s): 19071 - 19076
    09/17/2019 Authors: Rasheed MAU; Hickman CJ; McGrew M; Sowers SB; Mercader S; Hopkins A; Grimes V; Yu T; Wrammert J; Mulligan MJ
  • The game-changing nature of early and ongoing community engagement in HIV prevention efficacy trials: The AMP studies' experience (HVTN 703/HPTN 081 & HVTN 704/HPTN 085)
    Volume: 22 Page(s): 34 - 34
    07/01/2019 Authors: Andrasik M; Broder G; Lucas J; Davis J; White R; Luthuli N; Baepanye K; Oseso L; Wallace S; Ennis N
  • Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood.
    Open Forum Infect Dis Volume: 6 Page(s): ofy352
    01/01/2019 Authors: El Sahly HM; Gorchakov R; Lai L; Natrajan MS; Patel SM; Atmar RL; Keitel WA; Hoft DF; Barrett J; Bailey J
  • Tetravalent Janssen Mosaic Ad26/Protein HIV Vaccine Shows Increased Clade C Env-specific CD4+T-cell and Antibody Responses Versus Trivalent Vaccine
    Volume: 34 Page(s): 187 - 187
    10/01/2018 Authors: Tomaras GD; Montefiori D; Cohen KW; Heptinstall J; De Rosa SC; Sawant S; Baden LR; Goepfert PA; Keefer MC; Edupuganti S
  • Immune Responses to PENNVAX-GP (R) HIV DNA Vaccine Plus IL-12 Are Equivalent or Superior When Delivered by Intradermal vs. Intramuscular Electroporation
    Volume: 34 Page(s): 45 - 45
    10/01/2018 Authors: Edupuganti S; De Rosa S; Huang Y; Han X; Shao M; Elizaga M; Swann E; Polakowski L; Kalams S; Keefer M
  • Increased Breadth of T-cell Responses After Mosaic HIV Vaccination in Humans (HVTN 106)
    Volume: 34 Page(s): 31 - 31
    10/01/2018 Authors: Frahm N; Fiore-Gartland A; Malhi H; Baden LR; Walsh SR; Cohen KW; Elizaga M; Goepfert PA; Edupuganti S; Pantaleo G
  • Antibody Mediated Prevention: Proof-of-concept, Randomized, Blinded, Placebo-controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1
    Volume: 34 Page(s): 186 - 186
    10/01/2018 Authors: Edupuganti S; Mgodi N; Karuna S; Andrew P; Kochar N; De Camp A; Takuva S; Anderson M; De La Greca R; Lorenzo MG
  • Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People
    Volume: 34 Page(s): 186 - 186
    10/01/2018 Authors: Andrew P; Andrasik M; Thommes E; deCamp A; Kochar N; Karg C; Greene E; Tindale I; Lucas J; Broder G
  • Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials.
    Lancet Volume: 391 Page(s): 552 - 562
    02/10/2018 Authors: Gaudinski MR; Houser KV; Morabito KM; Hu Z; Yamshchikov G; Rothwell RS; Berkowitz N; Mendoza F; Saunders JG; Novik L
  • Innate, T-, and B-Cell Responses in Acute Human Zika Patients.
    Clin Infect Dis Volume: 66 Page(s): 1 - 10
    01/06/2018 Authors: Lai L; Rouphael N; Xu Y; Natrajan MS; Beck A; Hart M; Feldhammer M; Feldpausch A; Hill C; Wu H
  • Origin and differentiation of human memory CD8 T cells after vaccination.
    Nature Volume: 552 Page(s): 362 - 367
    12/21/2017 Authors: Akondy RS; Fitch M; Edupuganti S; Yang S; Kissick HT; Li KW; Youngblood BA; Abdelsamed HA; McGuire DJ; Cohen KW
  • Tularemia vaccine: Safety, reactogenicity, "Take" skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain - A phase 2 randomized clinical Trial.
    Vaccine Volume: 35 Page(s): 4730 - 4737
    08/24/2017 Authors: Mulligan MJ; Stapleton JT; Keitel WA; Frey SE; Chen WH; Rouphael N; Edupuganti S; Beck A; Winokur PL; El Sahly HM
  • The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled, phase 1 trial.
    Lancet Volume: 390 Page(s): 649 - 658
    08/12/2017 Authors: Rouphael NG; Paine M; Mosley R; Henry S; McAllister DV; Kalluri H; Pewin W; Frew PM; Yu T; Thornburg NJ
  • Basis and Statistical Design of the Passive HIV-1 Antibody Mediated Prevention (AMP) Test-of-Concept Efficacy Trials.
    Stat Commun Infect Dis Volume: 9
    01/01/2017 Authors: Gilbert PB; Juraska M; deCamp AC; Karuna S; Edupuganti S; Mgodi N; Donnell DJ; Bentley C; Sista N; Andrew P
  • Biphasic Zika Illness With Rash and Joint Pain.
    Open Forum Infect Dis Volume: 4 Page(s): ofx133
    01/01/2017 Authors: Edupuganti S; Natrajan MS; Rouphael N; Lai L; Xu Y; Feldhammer M; Hill C; Patel SM; Johnson SJ; Bower M
  • Pericarditis Associated With Acute Zika Virus Infection in a Returning Traveler.
    Open Forum Infect Dis Volume: 4 Page(s): ofx103
    01/01/2017 Authors: Waggoner JJ; Rouphael N; Xu Y; Natrajan M; Lai L; Patel SM; Levit RD; Edupuganti S; Mulligan MJ
  • Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus.
    Proc Natl Acad Sci U S A Volume: 113 Page(s): 7852 - 7857
    07/12/2016 Authors: Priyamvada L; Quicke KM; Hudson WH; Onlamoon N; Sewatanon J; Edupuganti S; Pattanapanyasat K; Chokephaibulkit K; Mulligan MJ; Wilson PC
  • Recognition of influenza H3N2 variant virus by human neutralizing antibodies.
    JCI Insight Volume: 1
    07/07/2016 Authors: Bangaru S; Nieusma T; Kose N; Thornburg NJ; Finn JA; Kaplan BS; King HG; Singh V; Lampley RM; Sapparapu G
  • Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-nave subjects.
    Vaccine Volume: 33 Page(s): 5225 - 5234
    09/22/2015 Authors: Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P
  • First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Vesicular Stomatitis Virus Human Immunodeficiency Virus-1 gag Vaccine (HVTN 090).
    Open Forum Infect Dis Volume: 2 Page(s): ofv082
    09/01/2015 Authors: Fuchs JD; Frank I; Elizaga ML; Allen M; Frahm N; Kochar N; Li S; Edupuganti S; Kalams SA; Tomaras GD
  • Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons 18 Years Old.
    J Infect Dis Volume: 212 Page(s): 552 - 561
    08/15/2015 Authors: Keitel WA; Jackson LA; Edupuganti S; Winokur PL; Mulligan MJ; Thornburg NJ; Patel SM; Rouphael NG; Lai L; Bangaru S
  • Characterization of long-lived human memory CD8 T cells specific to yellow fever virus
    Volume: 194
    05/01/2015 Authors: Yang S; Akondy R; Youngblood B; Edupuganti S; Mulligan M; Ahmed R
  • Initial viral load determines the magnitude of the human CD8 T cell response to yellow fever vaccination.
    Proc Natl Acad Sci U S A Volume: 112 Page(s): 3050 - 3055
    03/10/2015 Authors: Akondy RS; Johnson PLF; Nakaya HI; Edupuganti S; Mulligan MJ; Lawson B; Miller JD; Pulendran B; Antia R; Ahmed R
  • DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.
    PLoS One Volume: 10 Page(s): e0125914
    01/01/2015 Authors: Ledgerwood JE; Bellamy AR; Belshe R; Bernstein DI; Edupuganti S; Patel SM; Renehan P; Zajdowicz T; Schwartz R; Koup R
  • Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations.
    Vaccine Volume: 33 Page(s): 163 - 173
    01/01/2015 Authors: Frey SE; Bernstein DI; Brady RC; Keitel WA; El Sahly H; Rouphael NG; Mulligan MJ; Atmar RL; Edupuganti S; Patel SM
  • Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.
    Open Forum Infect Dis Volume: 1 Page(s): ofu102
    12/01/2014 Authors: Mulligan MJ; Bernstein DI; Frey S; Winokur P; Rouphael N; Dickey M; Edupuganti S; Spearman P; Anderson E; Graham I
  • Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults.
    J Infect Dis Volume: 210 Page(s): 1270 - 1274
    10/15/2014 Authors: Callahan ST; Wolff M; Hill HR; Edwards KM; NIAID Vaccine and Treatment Evaluation Unit (VTEU) Pandemic H1N1 Vaccine Study Group
  • Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    JAMA Volume: 312 Page(s): 1420 - 1428
    10/08/2014 Authors: Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P
  • Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    JAMA Volume: 312 Page(s): 1409 - 1419
    10/08/2014 Authors: Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P
  • Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans.
    Proc Natl Acad Sci U S A Volume: 111 Page(s): 13133 - 13138
    09/09/2014 Authors: Ellebedy AH; Krammer F; Li G-M; Miller MS; Chiu C; Wrammert J; Chang CY; Davis CW; McCausland M; Elbein R
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
    J Infect Dis Volume: 210 Page(s): 99 - 110
    07/01/2014 Authors: Goepfert PA; Elizaga ML; Seaton K; Tomaras GD; Montefiori DC; Sato A; Hural J; DeRosa SC; Kalams SA; McElrath MJ
  • Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.
    J Infect Dis Volume: 210 Page(s): 99 - 110
    07/01/2014 Authors: Goepfert PA; Elizaga ML; Seaton K; Tomaras GD; Montefiori DC; Sato A; Hural J; DeRosa SC; Kalams SA; McElrath MJ
  • In response.
    Am J Trop Med Hyg Volume: 89 Page(s): 1226 - 1227
    12/01/2013 Authors: Edupuganti S; Mulligan MJ; Eidex RB; Cetron M; Marfin AA
  • A Recombinant Vesicular Stomatitis Virus (rVSV) HIV-1 Gag Vaccine Is Safe and Immunogenic in Healthy, HIV-1 Uninfected Phase I Trial Participants
    Volume: 29 Page(s): A74 - A75
    11/01/2013 Authors: Fuchs JD; Frank I; Elizaga M; Kochar N; Allen M; Frahm N; Carter DK; Li S; Edupuganti S; Kalams S
  • Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    J Infect Dis Volume: 208 Page(s): 818 - 829
    09/01/2013 Authors: Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I
  • Enrollment in YFV Vaccine Trial: An Evaluation of Recruitment Outcomes Associated with a Randomized Controlled Double-Blind Trial of a Live Attenuated Yellow Fever Vaccine.
    Trop Med Surg Volume: 1 Page(s): 117
    04/15/2013 Authors: Frew PM; Shapiro ET; Lu L; Edupuganti S; Keyserling HL; Mulligan MJ
  • A randomized, double-blind, controlled trial of the 17D yellow fever virus vaccine given in combination with immune globulin or placebo: comparative viremia and immunogenicity.
    Am J Trop Med Hyg Volume: 88 Page(s): 172 - 177
    01/01/2013 Authors: Edupuganti S; Eidex RB; Keyserling H; Akondy RS; Lanciotti R; Orenstein W; del Rio C; Pan Y; Querec T; Lipman H
  • Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1.
    Lancet Infect Dis Volume: 12 Page(s): 966 - 976
    12/01/2012 Authors: Whitaker JA; Rouphael NG; Edupuganti S; Lai L; Mulligan MJ
  • Detection of anti-yellow fever virus immunoglobulin m antibodies at 3-4 years following yellow fever vaccination.
    Am J Trop Med Hyg Volume: 87 Page(s): 1112 - 1115
    12/01/2012 Authors: Gibney KB; Edupuganti S; Panella AJ; Kosoy OI; Delorey MJ; Lanciotti RS; Mulligan MJ; Fischer M; Staples JE
  • Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.
    J Infect Dis Volume: 206 Page(s): 811 - 820
    09/15/2012 Authors: Jackson LA; Chen WH; Stapleton JT; Dekker CL; Wald A; Brady RC; Edupuganti S; Winokur P; Mulligan MJ; Keyserling HL
  • Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.
    Proc Natl Acad Sci U S A Volume: 109 Page(s): 9047 - 9052
    06/05/2012 Authors: Li G-M; Chiu C; Wrammert J; McCausland M; Andrews SF; Zheng N-Y; Lee J-H; Huang M; Qu X; Edupuganti S
  • Robust Immunogenicity after HIV DNA Vaccination with IL-12 Plasmid Cytokine Adjuvant Delivered via Electroporation in HIV Uninfected Adults
    Volume: 27 Page(s): A131 - A131
    10/01/2011 Authors: Kalams SA; Edupuganti S; Elizaga M; Metch B; Eldridge J; Sherwat A; De Rosa S; Khan AS; Sardesai N; Weiner DB
  • Fusarium falciforme vertebral abscess and osteomyelitis: case report and molecular classification.
    J Clin Microbiol Volume: 49 Page(s): 2350 - 2353
    06/01/2011 Authors: Edupuganti S; Rouphael N; Mehta A; Eaton M; Heller JG; Bressler A; Brandt M; O'Donnell K
  • Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant.
    J Infect Dis Volume: 203 Page(s): 666 - 673
    03/01/2011 Authors: Belshe RB; Frey SE; Graham I; Mulligan MJ; Edupuganti S; Jackson LA; Wald A; Poland G; Jacobson R; Keyserling HL
  • Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.
    J Exp Med Volume: 208 Page(s): 181 - 193
    01/17/2011 Authors: Wrammert J; Koutsonanos D; Li G-M; Edupuganti S; Sui J; Morrissey M; McCausland M; Skountzou I; Hornig M; Lipkin WI
  • The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.
    J Immunol Volume: 183 Page(s): 7919 - 7930
    12/15/2009 Authors: Akondy RS; Monson ND; Miller JD; Edupuganti S; Teuwen D; Wu H; Quyyumi F; Garg S; Altman JD; Del Rio C
  • Molecular signature of human virus specific effector CD8+T cells
    JOURNAL OF IMMUNOLOGY Volume: 182
    04/01/2009 Authors: Akondy RS; Miller JD; Doho G; Wu H; Zilliox M; de Rio C; Mulligan MJ; Edupuganti S; Haining WN; Ahmed R
  • Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults.
    AIDS Res Hum Retroviruses Volume: 25 Page(s): 103 - 114
    01/01/2009 Authors: Harro CD; Robertson MN; Lally MA; O'Neill LD; Edupuganti S; Goepfert PA; Mulligan MJ; Priddy FH; Dubey SA; Kierstead LS
  • Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas.
    J Travel Med Volume: 16 Page(s): 46 - 52
    01/01/2009 Authors: Whitaker JA; Franco-Paredes C; del Rio C; Edupuganti S
  • Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.
    Immunity Volume: 28 Page(s): 710 - 722
    05/01/2008 Authors: Miller JD; van der Most RG; Akondy RS; Glidewell JT; Albott S; Masopust D; Murali-Krishna K; Mahar PL; Edupuganti S; Lalor S
  • Cytotoxic T-lymphocyte responses to canarypox vector-based HIV vaccines in HIV-seronegative individuals: a meta-analysis of published studies.
    HIV Clin Trials Volume: 5 Page(s): 259 - 268
    01/01/2004 Authors: Edupuganti S; Weber D; Poole C
  • Characterization of the gene cassette required for biosynthesis of the (alpha1-->6)-linked N-acetyl-D-mannosamine-1-phosphate capsule of serogroup A Neisseria meningitidis.
    J Bacteriol Volume: 180 Page(s): 1533 - 1539
    03/01/1998 Authors: Swartley JS; Liu LJ; Miller YK; Martin LE; Edupuganti S; Stephens DS
  • From the Centers for Disease Control. Malaria in an immigrant and travelers--Georgia, Vermont, and Tennessee, 1996.
    JAMA Volume: 278 Page(s): 541 - 542
    08/20/1997
  • Malaria in an immigrant and travelers - Georgia, Vermont, and Tennessee, 1996 (Reprinted from MMWR, vol 46, pg 536-539, 1997)
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION Volume: 278 Page(s): 541 - 542
    08/20/1997 Authors: delRio C; Edupuganti S; Cassoobhoy M; Taylor T; Ricaurte F; Mogielnicki RP; Soufleris A; Allen L; Beville J; Moore W
  • Thyroid function in children with different lipoprotein profiles: observations in a biracial (black/white) population--the Bogalusa Heart Study.
    Am J Med Sci Volume: 313 Page(s): 80 - 84
    02/01/1997 Authors: Edupuganti S; Svec F; Bao W; Srinivasan SR; Berenson GS
  • Capsule switching of Neisseria meningitidis.
    Proc Natl Acad Sci U S A Volume: 94 Page(s): 271 - 276
    01/07/1997 Authors: Swartley JS; Marfin AA; Edupuganti S; Liu LJ; Cieslak P; Perkins B; Wenger JD; Stephens DS
  • THE RELATIONSHIP BETWEEN TSH DETERMINED BY AN ULTRASENSITIVE ASSAY AND SERUM-LIPIDS IN CHILDREN - THE BOGALUSA HEART-STUDY
    CLINICAL RESEARCH Volume: 39 Page(s): A871 - A871
    12/01/1991 Authors: EDUPUGANTI S; SVEC F; BAO WH; SRINIVASAN SR; BERENSON GS
Read more publications Fewer publications
Directory
  • Faculty Profiles
Emory University Homepage

Contact & Location

Emory University School of Medicine
100 Woodruff Circle
Atlanta, GA  30322 USA
  • Contact Us
  • Maps & Directions
  • Careers

Information For

  • Alumni
  • Faculty & Staff
  • Patients
  • Residents & Fellows
  • Students
Support the School of Medicine School of Medicine Intranet
facebook facebook twitter twitter linkedin linkedin instagram instagram youtube youtube
© 2025 Emory University
  • Privacy Policy
  • Emergency Information
  • EEO Employer-Disability/Veteran Statements